SCHEMBL3977154

SCHEMBL3977154

O=C(c1ccc(F)cc1)c1cccc(N2CCN(C3CCCC3)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
L3MBTL3 Q96JM7 1/20 0.53
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KDM4E B2RXH2 3/20 0.51
TP53 P04637 2/20 0.51
TSHR P16473 2/20 0.51
MAPK1 P28482 2/20 0.51
ALDH1A1 P00352 2/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HTT P42858 2/20 0.50
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.47
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233375 0.78 NPC1 (0.61) HRH3L3MBTL1L3MBTL3NPC1RAB9A
SCHEMBL5233367 0.78 NPC1 (0.61) HRH3L3MBTL1L3MBTL3NPC1RAB9A
SCHEMBL2773822 0.77 HTT (0.53) L3MBTL1L3MBTL3TSHRALDH1A1HTT
SCHEMBL2773819 0.77 HTT (0.53) L3MBTL1L3MBTL3TSHRALDH1A1HTT
SCHEMBL3977542 0.75 ALDH1A1 (0.50) HRH3L3MBTL1L3MBTL3NPC1RAB9A
SCHEMBL13648854 0.74 ALDH1A1 (0.66) L3MBTL1L3MBTL3NPC1RAB9AKDM4E
Hydrochloric Acid SCHEMBL3974709 0.74 ALDH1A1 (0.49) HRH3L3MBTL1L3MBTL3NPC1RAB9A
SCHEMBL22848339 0.74 L3MBTL3 (0.56) L3MBTL1L3MBTL3NPC1TP53MAPK1
Hydrochloric Acid SCHEMBL3967625 0.73 ALDH1A1 (0.64) L3MBTL1NPC1RAB9AKDM4ETP53
SCHEMBL3965782 0.73 POLB (0.67) L3MBTL1RAB9AKDM4ETP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HRH3, HRH2, HRH4 HRH3 1/4885L3MBTL1 3580/4885L3MBTL3 3701/4885
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HRH3, HRH2, HRH4 HRH3 1/4885L3MBTL1 3580/4885L3MBTL3 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.